Method Of Treating Attention Deficit Disorders With D-Threo Methylphenidate

Abstract

Methods for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS while minimizing drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential by administration of d-threo-methylphenidate or pharmaceutically acceptable salts thereof.

1 . A method of treating Attention Deficit Hyperactivity Disorder comprising administrating on a daily basis to a human having Attention Deficit Hyperactivity Disorder, 5 to 50 mg of D-threo methylphenidate, or a pharmaceutically acceptable salt thereof, substantially free of L-threo methylphenidate, wherein the D-threo methylphenidate, or pharmaceutically acceptable salt, is mixed with a pharmaceutically acceptable carrier, diluent, or excipient. 
   
   
       2 . The method according to  claim 1  wherein the amount of D-threo methylphenidate administered is 5 mg per day. 
   
   
       3 . The method according to  claim 1  wherein the amount of said D-threo methylphenidate, or a pharmaceutically equivalent salt thereof, is greater than 90% of the total amount of methylphenidate. 
   
   
       4 . The method according to  claim 4  wherein the amount of said D-threo methylphenidate, or a pharmaceutically equivalent salt thereof, is greater than 99% of the total amount of methylphenidate. 
   
   
       5 . The method according to  claim 1  wherein the amount of D-threo methylphenidate enhances therapeutic activity compared to racemic methylphenidate. 
   
   
       6 . The method according to  claim 1  wherein the administration is one to four times per day. 
   
   
       7 . The method according to  claim 1  wherein the amount of D-threo methylphenidate administered is 20 mg per day. 
   
   
       8 . The method according to  claim 1  wherein the amount of D-threo methylphenidate administered is 50 mg per day.